Research Paper

**Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).**

Coleman RE, FRCP¹, Collinson M, MSc², Gregory W, PhD², Marshall H, MSc² Bell R, FRACP³, Dodwell D, FRCR⁴, Keane M, MD⁵, Gil M, MD⁶, Barrett-Lee P, FRCR⁷, Ritchie D, FRCR⁸, Bowman A, FRCP⁹, Liversedge V, BSc², De Boer RH, FRACP¹⁰, Passos-Coelho JL, MD¹¹, O’Reilly S, FRCP¹², Bertelli G, FRCP¹³, Joffe J, FRCP¹⁴, Brown JE, FRCP¹, Wilson C, MRCP¹, Tercero JC, PhD¹⁵, Jean-Mairet J, PhD¹⁵, Gomis R, PhD¹⁶, Cameron D, FRCP*⁹

*Joint senior authors

¹Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield, UK on behalf of the NIHR Cancer Research Network

²Clinical Trials Research Unit, University of Leeds, Leeds, UK

³Andrew Love Cancer Centre, Geelong, Australia on behalf of VCOG

⁴St James Institute of Oncology, University of Leeds, UK

⁵University Hospital Galway, Ireland on behalf of Cancer Trials Ireland

⁶Institut Català d’Oncologia – IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain on behalf of SOLTI Breast Cancer Research Group

⁷Velindre Cancer Center, Whitchurch, Cardiff, UK

⁸Beatson West of Scotland Cancer Centre, Glasgow, UK

⁹Edinburgh Cancer Research Centre, Western General Hospital, University of Edinburgh, UK

¹⁰Royal Melbourne Hospital, Melbourne, Australia on behalf of VCOG

¹¹Hospital da Luz, Lisbon, Portugal on behalf of SOLTI Breast Cancer Research Group

¹²Cork University Hospital, Ireland on behalf of Cancer Trials Ireland

¹³Sussex Cancer Centre, Brighton, UK

¹⁴Huddersfield Royal Infirmary, Huddersfield, UK

¹⁵Inbiomotion SL, Barcelona, Spain

¹⁶Institute for Research in Biomedicine (IRB Barcelona), Barcelona Science and Technology Institute, CIBERONC and Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

The full list of recruiting centers is shown in the appendix

**Running title:** Adjuvant treatment with zoledronic acid in breast cancer: 10 year follow-up

**Address for correspondence:**

Professor Robert Coleman (r.e.coleman@sheffield.ac.uk)
Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, S10 2SJ, UK

Abstract

Adjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial (ISRCTN79831382) was designed to determine whether adjuvant zoledronic acid (ZOL) improves disease outcomes in EBC. Previous analyses showed no effect on overall outcomes but identified benefits in postmenopausal women. Here we present the long-term risks and benefits of adjuvant ZOL with 10-years follow-up.

Patients and methods: 3360 patients with stage II/III breast cancer were included in an academic, international, phase III, randomized, open label trial. Patients were followed up on a regular schedule until 10 years. Patients were randomized on a 1:1 basis to standard adjuvant systemic therapy +/- intravenous ZOL 4mg every 3-4 weeks x6, and then at reduced frequency to complete 5 years treatment. The primary outcome was disease free survival (DFS). Secondary outcomes included invasive DFS (IDFS), overall survival (OS), sites of recurrence, skeletal morbidity and treatment outcomes according to primary tumor amplification of the transcription factor, MAF. Pre-planned subgroup analyses focused on interactions between menopausal status and treatment effects.

Results: With a median follow up of 117 months [IQR 70.4-120.4), DFS and IDFS were similar in both arms (HR DFS=0.94, 95%CI=0.84-1.06, p=0.340; HR IDFS=0.91, 95%CI=0.82-1.02, p=0.116). However, outcomes remain improved with ZOL in postmenopausal women (HR DFS=0.82, 95%CI=0.67-1.00; HR IDFS=0.78, 95%CI=0.64-0.94). In the 79% of tested women with a MAF FISH negative tumor, ZOL improved IDFS (HR IDFS=0.75, 95%CI=0.58-0.97) and OS HR OS=0.69, 95%CI=0.50-0.94), irrespective of menopause. ZOL did not improve disease outcomes in MAF FISH+ tumors. Bone metastases as a first DFS recurrence (B DFS) were reduced with ZOL (HR B DFS=0.76, 95%CI=0.63-0.92, p=0.005). ZOL reduced skeletal morbidity with fewer fractures and skeletal events after disease recurrence. 30 cases of osteonecrosis of the jaw in the ZOL arm (1.8%) have occurred.
Conclusions: Disease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up. The biomarker MAF identified a patient subgroup that derived benefit from ZOL irrespective of menopausal status.
Introduction

Despite improvements in both early diagnosis and treatment, breast cancer remains the leading cause of cancer death in women in the developed world.¹ Late recurrence of the disease is frequent, especially to bone, with disseminated malignant cells seemingly able to evade adjuvant treatments and remain dormant, before re-activating and causing disease relapse many years after diagnosis.² Therapeutic strategies to improve disease outcomes include the use of bisphosphonates to affect the bone microenvironment.³

The AZURE trial is an academic study, designed to test whether treatment with the bisphosphonate, zoledronic acid (ZOL), could improve disease outcomes in patients with stage II/III breast cancer. Previous analyses after 752⁴ and 966⁵ disease free survival (DFS) events showed that, despite a reduction in the risk of developing bone metastases with ZOL, there was no effect on overall breast cancer recurrence. However, preplanned subgroup analyses identified benefit in women who were in established menopause at the time of study entry. This observation was subsequently confirmed by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis of adjuvant bisphosphonates,⁶ resulting in recommendations both in Europe⁷ and North America⁸ to consider use of adjuvant bisphosphonates in postmenopausal women with early breast cancer.

Here, we present the 10 year follow-up results from the AZURE trial and describe the effects of ZOL on disease relapse, skeletal morbidity, site(s) of recurrence, overall survival and toxicity. We also explore the interactive effects of menopausal status, age at diagnosis and the predictive biomarker MAF with ZOL on disease outcomes.

Methods

AZURE (BIG01/04) is an academic, prospective, randomised controlled phase III, open label multi-national and multi-center trial (ISRCTN79831382). The study design and patient eligibility have been described previously,⁴⁵ but, in summary, patients had histologically confirmed invasive breast cancer of any biological subtype with either pathologically
confirmed axillary lymph node metastases or a T3/T4 primary tumor. Patients were not eligible if there was clinical or imaging evidence of distant metastases prior to study entry, current or recent (previous year) use of bisphosphonates or pre-existing bone disease likely to require bone-targeted treatment. All patients gave written informed consent.

Between September 2003 and February 2006, 3360 patients from 174 centers were randomized on a 1:1 basis using a central automated 24-hour computer-generated telephone randomization system to receive (neo)adjuvant systemic therapy with (ZOL) or without (CONTROL) zoledronic acid. A minimization method was used to ensure balance in key prognostic and treatment variables across the two groups.4

ZOL 4mg was administered by intravenous (iv) infusion every 3-4 weeks for 6 doses, then 3 monthly x 8 and 6 monthly x 5 to complete 5 years treatment. Novartis Pharmaceuticals provided study-specific supplies of ZOL. Daily oral supplements containing calcium (400-1000mg) and vitamin D (200-500 IU) were recommended to all trial subjects during the first six months, and continued thereafter at the discretion of the treating physician.

Surgical management, the use and delivery of loco-regional external beam radiotherapy, timing of adjuvant treatments in relation to surgery and selection of chemotherapy and endocrine treatments were all decided in accordance with standard protocols at each participating institution. Trastuzumab was allowed in patients with HER2+ tumors after regulatory approval for adjuvant use in 2006.

Patients in both treatment arms were followed up on the same schedule to fit in with administration of ZOL (where allocated) during the first 5 years on trial. Thereafter, patients were reviewed annually until 10 years. Follow-up investigations were as clinically indicated with no protocol mandated imaging to identify sub-clinical metastatic disease. Dates of recurrence were backdated to the first clinical suspicion of relapse rather than the date confirmed.

The primary endpoint of the study was DFS, defined specifically for this study as any recurrence of breast cancer (except for ipsilateral operable invasive or in-situ relapse within a conserved breast) and death from any cause without recurrence. Secondary endpoints included invasive DFS (IDFS), defined according to STEEP guidelines;9 time to
bone metastasis at any time (TTBM) and as first DFS recurrence (B-DFS); overall survival (OS); skeletal morbidity including fractures before and after a DFS recurrence event, hypercalcaemia and skeletal related events (SREs) associated with bone metastases (need for radiotherapy, orthopaedic surgery and spinal cord compression). Pre-specified subgroup analyses included menopausal status of the patient prospectively defined at presentation and prior to randomisation as established (>5 years since menses), perimenopausal (within 5 years of menses), premenopausal (regular menses) or unknown. Exploratory analyses investigating treatment effects on site(s) of first recurrence, breast cancer specific survival and relationships between patient age at randomisation and outcomes were also performed.

Following the discovery that amplification of the v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MAF) gene predicted for benefits and harms of adjuvant ZOL in an earlier analysis of the AZURE trial, the long-term relationships between MAF amplification and treatment effects were evaluated. Primary tumor tissue blocks were collected from 1769/2710 (65%) patients treated at participating sites in the UK. An additional 650 patients were recruited from outside the UK. Site participation in the collection of tumor blocks was encouraged but not mandatory and, for logistical reasons, restricted to UK sites. The MAF biomarker analysis was completed on TMAs from these primary tumors.

All tumor blocks were sent to Sheffield for tissue microarray (TMA) construction where the location of invasive tumor within the tissue blocks was indicated by a single breast pathologist as a guide to the technician extracting the tissue cores for construction of the TMAs. Quadruplicate cores of 1 mm in diameter of each of the tumor tissue sample were arranged in 4 sets of 13 TMAs (150 samples each). All analyses are restricted to study participants who gave specific patient consent for the use of tissue samples.

The methodology for determining MAF status using a FISH based assay has been described previously. The MAF FISH test was performed on primary tumours preserved in tissue microarray format by an independent laboratory (Targos Molecular Pathology, Kassel, Germany, blinded to patient details and treatment allocation. A pre-specified cut-off for MAF positivity of ≥2.5 copies was defined prior to any analysis. Prediction of treatment
benefit was focused primarily on IDFS, rather than the AZURE specific definition of DFS, and OS to enable future validation in other studies.

DFS, IDFS and OS were investigated using Kaplan-Meier survival curves; time to bone metastases endpoints were calculated using cumulative incidence functions (CIFs). Deaths without diagnosis of bone metastases for TTBM and deaths without metastases and non-bone first DFS recurrences for B-DFS were considered competing-risk events. Differences between treatment arms were compared using the log-rank test and Cox’s proportional hazards model to adjust for minimization factors (excluding center).

Osteonecrosis of the jaw (ONJ) rates were calculated using CIFs, where deaths without diagnosis of ONJ were considered as competing-risk events.

Subgroup analyses were performed using Cox’s proportional hazards model to adjust for statistically significant factors in the overall analyses for DFS, IDFS, B-DFS and OS (lymph node involvement and tumour stage for all plus: ER status for DFS, IDFS and OS; menopausal status for OS; neoadjuvant therapy for IDFS). Predictive analyses assessing the interaction of MAF status with zoledronic acid were performed using a Cox’s proportional hazards model adjusted for minimization factors previously shown to impact on prognosis (node status, grade, T stage). The assumption of proportional hazards for each treatment arm was assessed by plotting the hazards over time (i.e. the log cumulative hazard plot from SAS’s LIFETEST procedure). A piecewise hazards approach was utilized to investigate the effect of ZOL in years 0-5 and 5-10 for IDFS in postmenopausal patients.

For the predictive MAF biomarker analyses, the response to zoledronic acid treatment was tested comparing control and ZOL groups. A predictive analysis, assessing the interaction of MAF status with treatment allocation, was performed using a Cox proportional hazards model. Only minimization factors identified as statistically significant in the prognostic analysis were included in the model to reduce potential overfitting. In addition, predictive analyses were carried out for patients who were unequivocally post-menopausal (>5 years since last menses) at trial entry separately to patients who were not post-menopausal (pre-menopausal, ≤5 years since menopause and menopausal status unknown), given the significant heterogeneity of treatment effect between established post-menopausal
patients and all other patients observed in the AZURE trial as a whole. The SAP for these biomarker tests was defined before any data analysis was performed with interactions between MAF+ve and effects of ZOL on disease outcomes by menopausal status pre-specified.

All analyses presented are adjusted analyses. Hazard ratios with 95% confidence intervals (CI) are presented. Hypothesis testing was two-sided with significance at 5%. No adjustments were made for multiplicity. P values are restricted to the ITT analyses (main study and biomarker subset) and, due to previous analyses\textsuperscript{4,5} should be considered descriptive rather than inferential. Analyses were carried out in SAS version 9.4 (SAS Institute Inc., Cary, NC).

**Results**

Baseline patient demographics, disease characteristics and systemic anticancer treatments were balanced across the two randomized study groups (Table 1). 3207 patients (95%) received chemotherapy (207 neoadjuvant chemotherapy), 2488 patients both chemotherapy and endocrine treatment(s) and 152 patients endocrine treatment(s) alone (CONSORT DIAGRAM, Figure 1).

With a median follow up of 117 months (interquartile range (IQR) 70.4-120.4 months) at the data-lock on 7th June 2016, there have been 1130 DFS, 1250 IDFS, 910 OS events and 781 breast cancer deaths [Table 2]. Follow-up was almost identical for ZOL (median 118, IQR 71.4-120.5 months) and CONTROL patients (median 116.3, IQR 69.2-120.4 months). Four ZOL patients were not evaluable for DFS or IDFS (3 metastatic disease at randomization, one neoadjuvant patient not proceeding to definitive surgery) and one CONTROL patient was not evaluable for IDFS (another primary tumor at randomization); all were censored at time zero in the relevant analysis.

The number of DFS (ZOL=555, CONTROL=575) and IDFS (ZOL=606, CONTROL=644) events were similar in both arms (HR\textsubscript{DFS}=0.94, 95%CI:0.84-1.06, P=0.340; HR\textsubscript{IDFS}=0.91, 95%CI:0.82-
1.02, P=0.116) [Figure 2A and 2B]. As with earlier analyses,\textsuperscript{4,5} ZOL improved DFS and IDFS in patients who were >5 years postmenopausal (ZOL=177, CONTROL=206 DFS events) at the time of randomization (HR\textsubscript{DFS}=0.82, 95%CI:0.67-1.00; HR\textsubscript{IDFS}=0.78, 95%CI:0.64-0.94) [Figure 2C and 2D]. The absolute difference in IDFS at 10 years was 7.8% (95%CI:1.4% to 14.2% [ZOL=59.9%, CONTROL=52.1%]). The benefits from treatment appear in the first five years (during treatment) following which the IDFS curves run parallel. The HRs were 0.68 (95%CI:0.53-0.87, P=0.002) and 0.89 (95%CI:0.65-1.21, P=0.456) in years 0-5 and 5-10 respectively. The absolute difference in IDFS between treatments averaged from five years onwards is consistent at about 6.5%.

Women who were not post-menopausal at study entry did not gain benefit for either DFS (ZOL=378, CONTROL=369 events; HR\textsubscript{DFS}=1.03, 95%CI:0.89-1.19) or IDFS (ZOL=413, CONTROL=411 events; HR\textsubscript{IDFS}=1.01, 95%CI:0.88-1.16). The test for interaction (TFI) by menopause on DFS was of borderline significance (Chi\textsuperscript{2}=3.25, P=0.07).

Bone metastases as a first DFS recurrence (B-DFS) were reduced with ZOL (ZOL=188, CONTROL=244 events; HR\textsubscript{B-DFS}=0.76, 95%CI:0.63-0.92, P=0.005) (Figure 3). The absolute difference in B-DFS at 10 years was 3.6% (95%CI:1.1% to 6.0% [ZOL=11.9%, CONTROL=15.5%]). Treatment effects on this endpoint were similar in postmenopausal (HR\textsubscript{B-DFS}=0.76, 95%CI:0.53-1.07) and non-postmenopausal women (HR\textsubscript{B-DFS}=0.77, 95%CI:0.61-0.96); TFI\textsubscript{B-DFS} by menopause Chi\textsuperscript{2}=0.005, P=0.94. Specific sites of bone metastases as first DFS recurrence by treatment allocation are shown in Table 3.

Extra-skeletal distant recurrence DFS (E-dDFS) events (ZOL=279, CONTROL=264) were similar in the two treatment groups. However heterogeneity of treatment effects on E-dDFS by menopause was seen. In postmenopausal women the HR for E-dDFS was 0.77 (95%CI:0.57-1.04), whereas it was 1.22 (95%CI:0.99-1.50) in non-postmenopausal women (TFI Chi\textsuperscript{2}=6.11, P=0.01).

Overall survival was similar in the two arms in the ITT analysis (HR\textsubscript{OS}=0.92 95%CI:0.81-1.05, P=0.24) [Figure 4A]. However in the postmenopausal cohort, improvements in OS (HR\textsubscript{OS}=0.84, 95%CI:0.67-1.04) [Figure 4B] and breast cancer mortality (HR=0.80, 95%CI:0.62-1.03) that approached statistical significance were seen. The absolute
difference in OS at 10 years was 4.4% (95%CI:-1.5% to 10.4% [ZOL=69.0%, CONTROL=64.6%]).

The MAF FISH test was assessable in 865 (26% of the entire AZURE cohort) patients. These patients had similar tumor and treatment characteristics (Table 4) and 10-year IDFS and OS outcomes to the entire AZURE cohort. Six hundred and eighty (79%) were MAF negative with ≤2.5 copies per cell (ZOL 321, CONTROL 359). ZOL significantly improved 10 year IDFS (HR\textsubscript{IDFS}=0.75, 95%CI:0.58-0.97, P=0.026), bone IDFS (HR\textsubscript{BDFS}=0.65, 95%CI:0.45-0.94, P=0.022) and OS (HR\textsubscript{OS}=0.69, 95%CI:0.50-0.94, P=0.019) in women with MAF negative tumors, irrespective of menopause (Figure 5). On the other hand, women with MAF positive tumors did not benefit from ZOL (HR\textsubscript{IDFS}=1.54, 95%CI:0.96-2.47, P=0.074) and OS (HR\textsubscript{OS}=1.40, 95%CI:0.83-2.33, P=0.204). Indeed, non-postmenopausal women with MAF positive tumors had much worse outcomes (HR\textsubscript{IDFS}=2.31, 95%CI:1.18-4.52, P=0.015; HR\textsubscript{OS}=2.28, 95%CI:1.07-4.82, P=0.032) driven largely by an increase in extra-skeletal recurrences in this patient sub-group (HR\textsubscript{E-DFS}=4.57, 95%CI:1.66-12.57, P=0.003).

Exploratory analyses of study treatment effects on DFS by age identified significant heterogeneity (Chi\textsuperscript{2}(trend)=7.70, P=0.0055). Patients who were <age 40 at diagnosis had a worse outcome with zoledronic acid (HR\textsubscript{DFS}=1.69; 95%CI:1.24-2.29) [Figure 6A]. This was due in part to more B-DFS events (HR\textsubscript{B-DFS}=1.59; 95%CI:1.01-2.49) [Figure 6B] but mainly reflected the markedly higher rates of DFS events outside bone (E-DFS) (HR\textsubscript{E-DFS}=2.06; 95%CI:1.43-2.97) in these young women treated with ZOL [Figure 6C]. The increase in relapse associated with zoledronic acid treatment in women aged <40 was associated also with worse survival outcomes (HR\textsubscript{OS}=1.56, 95%CI:1.09-2.22) at 10 years (Figure 7).

Treatment with ZOL reduced skeletal morbidity. 470 SREs occurred in 284/1681 (16.9%) of patients on ZOL compared with 700 SREs in 378/1678 (22.5%) of CONTROL patients (Table 5). Unlike in our earlier report on fractures,\textsuperscript{12} ZOL now not only reduced fracture incidence after a recurrence event (ZOL=52, CONTROL=79; P=<0.05) but also had an effect on fractures occurring in the absence of disease recurrence (ZOL=143, CONTROL=193; P=<0.05)).
Further follow up has not identified any new safety concerns since the previous safety publication. 13 30 confirmed cases of osteonecrosis of the jaw (ONJ), all in the zoledronic acid arm, have occurred (Figure 8) with 4 occurring after a relapse in bone and use of a bisphosphonate in the metastatic setting and only 4 further cases have been reported since the previous detailed analysis of ONJ reported earlier. 14 The cumulative incidence of ONJ is 1.8% (95%CI:1.2%-2.5%). There have been no reports of atypical femoral fracture.

Discussion

AZURE is one of the largest phase III studies of adjuvant bisphosphonates, and the first to report results with 10 years of follow-up. For the entire ITT population, although zoledronic acid reduced bone metastases as a first DFS recurrence, this did not translate into significant effects on DFS, IDFS or OS. However, treatment benefits in women who were in established menopause at the time of randomization persist out to ten years with a clinically and statistically significant 6.5% absolute IDFS benefit and a trend for improved breast cancer specific mortality. Our findings remain consistent with those reported in the EBCTCG meta-analysis6.

In women who were not in established menopause at the time of randomization, although there was a reduction in the risk of bone metastases as a first DFS recurrence, this did not translate into benefits in DFS, IDFS or OS. Indeed in the youngest patients included in this study (aged <40), zoledronic acid treatment was associated with an increase in relapse, especially at extra-skeletal sites, and worse overall survival, suggesting that inhibition of bone resorption in young women may promote displacement and/or increase dissemination of viable tumor cells to other organs.

MAF is a transcription factor of the AP-1 family encoded within 16q. MAF regulates the expression of a set of genes that collectively support several steps of breast cancer cell metastasis and progression15 epithelial-mesenchymal transition,16 macrophage function and a number of interactions within the bone marrow niche including cell adhesion.17 Evaluation of the biomarker MAF using a FISH assay to prospectively define MAF amplification appeared to identify the population of women likely to benefit from adjuvant
ZOL that avoids the imprecise assessment of menopause and impacts of treatment on ovarian function. The majority of women (79%) was deemed to be MAF negative and, in this biomarker defined population, ZOL was associated with relative risk reductions at 10 years of 35% for BDFS, 25% for IDFS and 31% for OS irrespective of the postmenopausal status of the patient at study entry. The predictive power of the MAF test has increased with further follow-up since our original observations. Women with a MAF positive tumor do not benefit from ZOL and, in those who were not postmenopausal at study entry, MAF positivity was associated with a 4-5 fold risk increase in disease recurrence outside bone and worse survival with ZOL use.

The mechanisms underpinning the inter-relationships between MAF status and treatment effects are unclear. MAF over-expression appears to influence trafficking of disseminated tumour cells away from the bone microenvironment where bisphosphonates can influence the tumour and stromal interactions, perhaps through additional inhibitory effects on adhesion molecules and/or macrophage function, that may be influenced by bisphosphonates, and encourage onward metastasis within extra-skeletal sites. We are currently investigating the impact of MAF status in preclinical models of bone metastasis and intend to try and validate the predictive ability of MAF using the primary tumors and trial data from the NSABP-B34 study of adjuvant oral clodronate. If our findings in AZURE are confirmed, MAF could be used in the future to select patients for adjuvant bisphosphonate treatment.

Although adverse breast cancer mortality in young women was not identified in the EBCTCG meta-analysis, there was significant heterogeneity of treatment effect in breast cancer mortality across age groups (Chi² for trend =3.9, P=0.05) and worse survival was reported in one of the early clodronate trials that recruited a large proportion of younger women. Our results serve as a timely reminder that manipulating the host environment, either intentionally as a cancer treatment strategy or as a bystander effect of other therapeutic interventions, has the potential to cause harm as well as good.

Of note, women aged 40-50, many of whom would likely have experienced chemotherapy-induced amenorrhea (data not collected), did not appear to gain benefit. Zoledronic acid was administered for five years and, due to the very long retention of the drug in the
skeleton\textsuperscript{19} with continuing effects on bone metabolism expected throughout much if not all of the additional 5 years of follow-up, manipulation of the bone environment did not appear to modify the late emergence of tumor cells from the dormant state. The benefits observed from adjuvant bisphosphonates in postmenopausal women would seem to argue for effects on early events in the metastatic process, perhaps including seeding of tumor cells to osteoblastic and other cellular niches in the bone marrow and/or an influence on tumor dormancy within a postmenopausal bone micro-environment, rather than on later steps such as emergence from dormancy and onward dissemination.

Adjuvant zoledronic acid was associated with a reduction in skeletal morbidity with fewer fractures during follow-up and a reduction in SREs related to metastatic bone disease. Improvements in the structural integrity of bone achieved with ZOL appear to persist beyond treatment cessation with a carry-over effect that reduces the morbidity associated with metastatic disease even though most patients (data not shown) received bone targeted treatment after a bone relapse.

Since the first report of the AZURE trial\textsuperscript{4} and the suggestion that the benefit of adjuvant bisphosphonates might be restricted to women with low levels of reproductive hormones, as in ABCSG-12\textsuperscript{20} and the pre-defined subgroup of women in AZURE with established menopause (defined as >5 years since last menses), there have been many attempts to try and validate this hypothesis. NSABP B34 identified possible benefits from adjuvant oral clodronate in women >50 at time of randomization\textsuperscript{21} and the GAIN investigators suggested improved outcomes in older women (aged >60) with daily oral ibandronate.\textsuperscript{22}

The persistent benefits seen in AZURE at 10 years, with fewer bone relapses and improved DFS and breast cancer mortality in postmenopausal women, argue for inclusion of a bisphosphonate into adjuvant treatment programs from the outset. The lack of benefits in women who will have become menopausal, either through ageing or the effects of chemotherapy during the course of breast cancer treatment, should discourage the use of delayed intervention of a bisphosphonate in the hope that this will also bring about benefits in terms of breast cancer relapse. Such a strategy is worthy of appropriate clinical trials but, currently, there is no evidence to support such an approach.
To address relationships between treatment benefit and menopausal status more comprehensively, the EBCTCG conducted a meta-analysis of >18,000 women included in randomized trials of adjuvant bisphosphonates with a specific aim to test the hypothesis that treatment benefits were related to menopausal status of the patient at the time bisphosphonates are initiated. This individual patient meta-analysis identified relative risk reductions in both the development of bone metastases and death from breast cancer at 10 years of 28% (P=0.0002) and 18% (P=0.002) respectively in postmenopausal women but no suggestion of benefits in those who were premenopausal at initiation of treatment, even though many of these would have become postmenopausal during follow-up. Exclusion of the hypothesis generating studies (ABCSD-12 and AZURE) did not materially change the study findings.

These results have led to supportive clinical guidelines in Europe and North America, a consensus recommendation by a European expert group to incorporate adjuvant bisphosphonates into routine clinical care and adoption of these recommendations in some health care systems. Despite the clinically important effects on breast cancer mortality, global acceptance has been slow, in part due a lack of regulatory approval for these generic medicines but also due to the finding that these benefits relate only to a subset of patients that is somewhat imprecise in its definition and also because mechanistic explanations for the findings remain unclear. The relationship between MAF status in the primary tumor and treatment outcome, if confirmed, may improve adherence to clinical guidelines.

There are some limitations to our study findings. Adjuvant systemic treatments have evolved since AZURE started in 2003. Most notably, the treatment of HER2+ breast cancer with trastuzumab has been standard treatment since 2006 and also the clear preference for the routine use of aromatase inhibitors over tamoxifen for postmenopausal ER+ breast cancer is well established with extended (> 5 years) use in some women. Less than half of the HER2 positive patients included in AZURE received trastuzumab and only around two thirds of women received an aromatase inhibitor, with most use being after a few years of tamoxifen rather than as initial endocrine treatment. However, the consistent benefits seen in the meta-analysis within the postmenopausal population, irrespective of clinic-
pathologic (no differences by histologic grade or nodal involvement) and biological subtypes (no differences by ER status) suggest that these results remain valid.

Finally, if an adjuvant bisphosphonate is to be used, which agent and schedule should be recommended? Both the meta-analysis and the initial report of the SWOG-0307 study\textsuperscript{24} suggest the benefits are similar for zoledronic acid, daily oral clodronate and daily oral ibandronate. The AZURE and SWOG-0307 schedule of zoledronic acid is intensive and associated with a small but not insignificant rate of ONJ. In the absence of clear evidence of a dose response relationship, a less intensive regimen of zoledronic acid, as pioneered by the ABCSG,\textsuperscript{21} or daily oral therapy with clodronate or ibandronate seem reasonable. Interestingly the use of adjuvant denosumab in early breast cancer, despite its ability to reduce the frequency of aromatase inhibitor associated fractures,\textsuperscript{25} failed in the large randomized D-CARE (NCT01077154) study to meet the primary objective of improving bone metastases free survival. IDFS and OS were also similar and there was no suggestion of a treatment interaction with menopausal status.\textsuperscript{26} The lack of disease benefits from denosumab also suggest that inhibition of bone resorption is necessary but not sufficient to prevent metastases. Bisphosphonates have multiple other cellular effects beyond osteoclast inhibition including effects on tumor cell adhesion, angiogenesis and immune function.\textsuperscript{27} Further research is required to understand whether some or all of these “off target” effects are clinically relevant.

Acknowledgements:

We would like to express our sincere gratitude to the 3360 patients who took part in this trial. We gratefully acknowledge the contribution of all investigators and research staff at the 174 recruiting centres (United Kingdom 123 centers, 2710 patients; Australia 28 centers, 226 patients; Eire 10 centers, 247 patients; Spain 8 centers, 107 patients; Thailand 2 centers, 25 patients; Taiwan 2 centers, 13 patients; Portugal 1 center, 32 patients - see appendix), the staff at the clinical trials research units in the United Kingdom (Clinical Trials Research Unit, University of Leeds; Institute for Cancer Research, Sutton; Clinical Trials Unit, Edinburgh; Cancer Research UK Clinical Trials Unit, University of Birmingham), Australia
(Victoria Co-operative Oncology Group), Ireland (Irish Clinical Oncology Research Group [now known as Cancer Trials Ireland]) and Spain (SOLTI Breast Cancer Research Group), the independent members and patient representatives on the Trial Steering and Data Monitoring Committees and Novartis Pharmaceuticals for their academic grant support.

**Research Support:**
The study was sponsored by the University of Sheffield, UK and received academic grant support from Novartis, supplemented in the UK by the infrastructure of the National Institute for Health Research Cancer Research Network (NIHR-CRN) and corresponding NHS funded research networks in Wales, Scotland and Northern Ireland and the Victorian Co-operative Oncology Group (VCOG) in Australasia as well as Weston Park Cancer Charity who funded the sample collection and storage for translational samples.

**Conflicts of interest**
Coleman reports grant funding to institution from Novartis, Bayer and Amgen, lecture fees from Amgen and a patent pending with Inbiomotion for the biomarker MAF. Brown reports grant funding from Novartis and Bayer and lecture/advisory fees from Amgen and Novartis. De Boer reports advisory board fees from Novartis. Gregory reports consultancy fees from Cologne and Janssen and a patent pending with Inbiomotion for the biomarker MAF. Collinson, Marshall and Liversedge all report grant support to their institution from Novartis. Tercero reports salary from Inbiomotion and patents pending related to the biomarker MAF. Jean-Mairet owns < 0.25% of Inbiomotion S.L and Gomis declares shares of Inbiomotion SL for a value of less than 10,000$ and patents pending related to the biomarker MAF. All other authors report no conflicts of interest.

**List of AZURE Investigators:**

| Title Initials/Forename & Surname | Hospitals - Australia |
|-----------------------------------|-----------------------|

16
| Title Initials/Forename & Surname | Hospitals - Ireland |
|---------------------------------|---------------------|
| Prof. Max Schwarz               | Alfred Hospital     |
| Dr. Shane White                 | Austin Hospital     |
| Dr. George Kannourakis          | Ballarat Oncology & Haematology Services |
| Dr. Craig Underhill             | Border Medical Oncology |
| Dr. Jacquie Chirgwin            | Box Hill Hospital   |
| Dr. Stephen Della-Fiorentina    | Campbelltown Hospital |
| Prof. Philip Beale              | Concord Repatriation General Hospital |
| Dr Bogda Koczwara               | Flinders Medical Centre |
| Dr Jacquelyn Thomson            | Frankston Hospital  |
| Dr Ross Jennens                 | Freemasons Hospital |
| Prof. Richard Bell              | Geelong Hospital    |
| Dr. Stephen Della-Fiorentina    | Liverpool Hospital  |
| Dr. Jacquie Chirgwin            | Maroondah Hospital  |
| Prof. Fran Boyle                | Mater Health Sydney |
| Dr. Mitchell Chipman            | Mercy Private Hospital |
| Dr. Michelle White              | Monash Medical Centre |
| Dr. Prue Francis                | Peter MacCallum Cancer Centre |
| Dr. Craig Lewis                 | Prince of Wales Hospital |
| Dr. Kevin Patterson             | Queen Elizabeth Hospital |
| Dr. Boris Chern                 | Redcliffe Hospital  |
| Dr. Richard De Boer            | Royal Melbourne Hospital |
| Dr. Sally Baron-Hay             | Royal North Shore Hospital |
| Prof. Fran Boyle                | Royal North Shore Hospital |
| Dr. Evan Bayliss                | Royal Perth Hospital |
| Dr. Jane Beith                  | Royal Prince Alfred Hospital |
| Dr. Karen White                 | St John of God Hospital |
| Dr. Ray Snyder                  | St Vincents Hospital, Melbourne |
| Prof. Ethesham Abdi             | Tweed Hospital      |
| Dr. Richard De Boer             | Western Hospital    |
| Dr Ray McDermott                | Adelaide & Meath National Children’s Hospital (AMNCH) |
| Dr Seamus O’Reilly              | Cork University Hospital |
| Title Initials/Forename & Surname | Hospitals - Portugal |
|----------------------------------|----------------------|
| Dr. José Luís Passos Coelho      | Instituto Português de Oncologia Francisco Gentil |

| Title Initials/Forename & Surname | Hospitals - Spain |
|----------------------------------|-------------------|
| Dr. José Manuel Aramendia        | Clínica Universitaria de Navarra |
| Dra. Ana Lluch                   | Hospital Clínico Universitario de Valencia |
| Dra. Raquel Andrés               | Hospital Clínico Universitario Lozano Blesa |
| Dr. Jose Ignacio Mayordomo       | Hospital Clínico Universitario Lozano Blesa |
| Dr. J. Gustavo Catalán          | Hospital Son Llatzer |
| Dra. Eva Mª Ciruelos            | Hospital Universitario 12 de Octubre |
| Dra. Patricia Gómez             | Hospital Universitario Vall D’Hebron |
| Dr. Federico Vázquez            | Hospital Universitario Vall D’Hebron |
| Dra. Mónica Arnedos             | Hospital Universitario Vall D’Hebron |
| Dr. Juan Miguel Gil             | ICO Del Hospital Duran I Reynals |
| Dr. Joan Brunet                 | ICO Del Hospital Josep Trueta |
| Dr. Ramón Colomer               | ICO Del Hospital Josep Trueta |

| Title Initials/Forename & Surname | Hospitals - Taiwan |
|----------------------------------|-------------------|
| Dr Shou Tung Chen                | Changhua Christian Hospital |
| Dr Tsai Wang Cheng               | National Cheng Kung University Hospital |

| Title Initials/Forename & Surname | Hospitals - Thailand |
|----------------------------------|----------------------|
| Dr. Patrapim Sunpaweravong       | Prince of Songkla University Hospital |
| Dr. Pittayapoom                  | Siriraj Hospital |
| Title Initials/Forename & Surname | Hospitals - United Kingdom |
|----------------------------------|---------------------------|
| Dr AW Hutcheon                   | Aberdeen Royal Infirmary   |
| Dr Radha Todd                    | Aberdeen Royal Infirmary   |
| Dr Athar Ahmed                   | Addenbrooke's Hospital     |
| Dr Anne Margaret Moody           | Addenbrooke's Hospital     |
| Dr Charles Wilson                | Addenbrooke's Hospital     |
| Dr Michael Crawford              | Airedale General Hospital  |
| Dr Clive Irwin                   | Alexandra Hospital         |
| Dr Rob Stein                     | Barnet General Hospital    |
| Dr Caroline Bridgewater          | Barnsley District General Hospital |
| Ms Caroline Lee                  | Barnsley District General Hospital |
| Dr Wendy Ella                    | Basildon Hospital          |
| Dr Colin Trask                   | Basildon Hospital          |
| Dr Ghislaine Fraser              | Beatson Oncology Centre    |
| Dr Diana Ritchie                 | Beatson Oncology Centre    |
| Dr JJ McAleer                    | Belfast City Hospital      |
| Dr P D J Hardman                 | Bishop Auckland General Hospital |
| Dr Nick Wadd                     | Bishop Auckland General Hospital |
| Dr Chris Bradley                 | Bradford Royal Infirmary   |
| Dr Chris Price                   | Bristol Haematology & Oncology Centre |
| Dr A Chaturvedi                  | Castle Hill Hospital (formerly Princess Royal Hospital) |
| Dr Saiqa Spensley                | Castle Hill Hospital (Formerly Princess Royal Hospital) |
| Dr Charles Lowdell               | Charing Cross Hospital     |
| Dr Roger Owen                    | Cheltenham General Hospital |
| Dr Omar Din                      | Chesterfield & North Derbyshire Royal Hospital |
| Dr Purohit                       | Chesterfield & North Derbyshire Royal Hospital |
| Dr Anne Armstrong                | Christie Hospital          |
| Dr Andrew Wardley                | Christie Hospital          |
| Dr David Spooner                 | City Hospital (Birmingham) |
| Dr Susan O’Reilly                | Clatterbridge Centre for Oncology |
| Name                  | Hospital                                    |
|-----------------------|---------------------------------------------|
| Dr Alan Slater        | Clatterbridge Centre for Oncology           |
| Dr Gillian Sadler     | Conquest Hospital (Hastings)                |
| Dr David Dodwell      | Cookridge Hospital                          |
| Mr Allan Corder       | County Hospital Hereford                    |
| Dr Graeme Lumsden     | Crosshouse Hospital                         |
| Dr Diana Ritchie      | Crosshouse Hospital                         |
| Dr P D J Hardman      | Darlington Memorial Hospital                |
| Dr Pamela Woodings    | Derbyshire Royal Infirmary                  |
| Dr Stephen Kelly      | Derriford Hospital                          |
| Dr S Kumar            | Dewsbury & District Hospital                |
| Dr Mohammad Butt      | Diana Princess of Wales Hospital, Grimsby   |
| Dr Paul Mack          | Diana Princess of Wales Hospital, Grimsby   |
| Dr Sundareswaran Ramakrishnan | Doncaster Royal Infirmary               |
| Dr Tamasin Evans      | Dumfries & Galloway Royal Infirmary         |
| Dr Kunkler            | Dumfries & Galloway Royal Infirmary         |
| Dr Alistair Ring      | Eastbourne District General Hospital        |
| Dr Angus Robinson     | Eastbourne District General Hospital        |
| Dr Philip Murray      | Essex County Hospital                       |
| Dr Peter Canney       | Falkirk & District Hospital                 |
| Dr Ghislaine Fraser   | Falkirk & District Hospital                 |
| Dr Judy Fraser        | Falkirk & District Hospital                 |
| Mr Simon Cawthorn     | Frenchay Hospital                           |
| Dr Mike Shere         | Frenchay Hospital                           |
| Dr Lydia Fresco       | George Eliot Hospital                       |
| Dr Leo Reinecke       | George Eliot Hospital                       |
| Dr Jane Worlding      | George Eliot Hospital                       |
| Dr Jill Bishop        | Glan Clwyd Hospital                         |
| Dr Paul Ellis         | Guy’s Hospital                              |
| Dr Mark Harries       | Guy’s Hospital                              |
| Dr Mary Grainne Dunn  | Hairmyers Hospital                          |
| Dr Hosney Yosef       | Hairmyers Hospital                          |
| Dr Peter Clark        | Halton General Hospital                     |
| Name                      | Hospital                          |
|---------------------------|-----------------------------------|
| Dr Susan O'Reilly         | Halton General Hospital           |
| Dr David Dodwell          | Harrogate District Hospital       |
| Dr Joji Joseph            | Harrogate District Hospital       |
| Dr Sarah Slater           | Homerton Hospital                 |
| Dr Johnathan Joffe        | Huddersfield Royal Infirmary      |
| Dr P D J Hardman          | James Cook University Hospital    |
| Dr Mark Churn             | Kidderminster Hospital            |
| Dr Eliot Sims             | King George Hospital              |
| Dr Samreen Ahmed          | King’s Mill Hospital              |
| Dr Steve Chan             | King’s Mill Hospital              |
| Dr Joanne Hornbuckle      | King’s Mill Hospital              |
| Dr Sarah Khan             | King’s Mill Hospital              |
| Dr Paul Ellis             | Kings College Hospital            |
| Dr Anne Rigg              | Kings College Hospital            |
| Dr David Dodwell          | Leeds General Infirmary           |
| Dr Elisabeth Murray       | Lincoln County Hospital           |
| Dr Mei-Lin Ah-See         | Luton & Dunstable Hospital        |
| Dr Andreas Makris         | Luton & Dunstable Hospital        |
| Dr Lisa Baraclough        | Macclesfield District General Hospital |
| R Hunter                  | Macclesfield District General Hospital |
| Pooja Jain                | Macclesfield District General Hospital |
| Dr Rema Jyothirmayi       | Maidstone Hospital                |
| Dr Indrajit Fernando      | Manor Hospital                    |
| Dr Rob Stein              | Middlesex Hospital (UCLH)         |
| Dr Andreas Makris         | Mount Vernon Hospital             |
| Dr Mark Churn             | New Cross Hospital                |
| Dr Kate Sumpter           | Newcastle General Hospital        |
| Dr Mark Verrill           | Newcastle General Hospital        |
| Dr John Dewar             | Ninewells Hospital                |
| Dr Alastair Thompson      | Ninewells Hospital                |
| Dr Adrian Harnett         | Norfolk & Norwich University Hospital |
| Dr Mark Napier            | North Devon District Hospital     |
| Name                        | Hospital                                      |
|-----------------------------|-----------------------------------------------|
| Miss Janet Walls            | North Manchester General Hospital             |
| Dr Jacqueline Newby         | North Middlesex University Hospital           |
| Dr Anthony Branson          | North Tyneside General Hospital               |
| Dr Craig Macmillan          | Northampton General Hospital                  |
| Dr Steve Chan               | Nottingham City Hospital                      |
| Dr Joanne Hornbuckle        | Nottingham City Hospital                      |
| Dr Karen McAdam             | Peterborough District Hospital                |
| Dr Elisabeth Murray         | Pilgrim Hospital                              |
| Dr S Kumar                  | Pinderfields Hospital                         |
| Dr Fiona Roberts            | Pontefract General Infirmary                  |
| Dr Somnath Mukherjee        | Prince Charles (as part of Velindre)          |
| Dr Dan Rea                  | Queen Elizabeth Hospital, Birmingham          |
| Prof Chris Poole            | Queen Elizabeth Hospital, Birmingham          |
| Dr Athar Ahmad              | Queen Elizabeth Hospital, King’s Lynn         |
| Dr Angela Bowman            | Queen Margaret Hospital                       |
| Dr Prabir Chakraborti       | Queen’s Hospital                              |
| Dr Eliot Sims               | Queen’s Hospital                              |
| Dr David Whillis            | Raigmore Hospital                             |
| Dr M Hatton                 | Rotherham General Hospital                    |
| Dr Gregory Wilson           | Royal Albert Edward Infirmary                 |
| Dr Jane Barrett             | Royal Berkshire Hospital                      |
| Dr Hugh Bishop              | Royal Bolton Hospital                         |
| Dr John Winstanley          | Royal Bolton Hospital                         |
| Dr Duncan A Wheatley        | Royal Cornwall Hospital                       |
| Dr Ann Hong                 | Royal Devon & Exeter Hospital                 |
| Dr Alison Jones             | Royal Free Hospital                           |
| Dr Gaffney                  | Royal Gwent Hospital                          |
| Mohammed Harb               | Royal Gwent Hospital                          |
| Dr R Jones (acting)         | Royal Gwent Hospital                          |
| Dr Carys Morgan             | Royal Gwent Hospital                          |
| Dr Simon Waters             | Royal Gwent Hospital                          |
| Virginia Hall               | Royal Hampshire County Hospital               |
| Name                              | Hospital                                   |
|----------------------------------|--------------------------------------------|
| Nick Murray                      | Royal Hampshire County Hospital            |
| Dr Sanjay Raj                    | Royal Hampshire County Hospital            |
| Dr Susan O’Reilly                | Royal Liverpool University Hospital        |
| Prof Ian E Smith                 | Royal Marsden Hospital                     |
| Dr John Yarnold                  | Royal Marsden Hospital                     |
| Dr Rajiv Agrawal                 | Royal Shrewsbury Hospital                  |
| Dr Stephen Houston               | Royal Surrey County Hospital               |
| Dr David Bloomfield              | Royal Sussex County Hospital               |
| Dr Rozenn Allerton               | Russells Hall Hospital                     |
| Dr Ellen Copson                  | Salisbury District Hospital                |
| Dr Kate Gregory                  | Salisbury District Hospital                |
| Dr Melanie Harvey                | Salisbury District Hospital                |
| Dr David Spooner                 | Sandwell General Hospital                  |
| Dr Thiagarajan Sreenivasan       | Scunthorpe General Hospital                |
| Dr Sunil Upadhyay                | Scunthorpe General Hospital                |
| Ramachandran Venkitaraman        | Scunthorpe General Hospital                |
| Dr Gianfilippo Bertelli          | Singleton Hospital                         |
| Prof Robert Leonard              | Singleton Hospital                         |
| Dr Andrew Stockdale              | Solihull Hospital                          |
| Dr Medy Tsalic                   | Solihull Hospital                          |
| Dr Joe M Bozzino                 | South Tyneside District Hospital           |
| Gourdarz Mazdai                  | South Tyneside District Hospital           |
| Ms Beatrix Weber                 | South Tyneside District Hospital           |
| Dr Peter Simmonds                | Southampton General Hospital                |
| Dr Anne Robinson                 | Southend Hospital                          |
| Dr Hyatt                         | Southport & Formby District General Hospital |
| Dr Christopher Gallagher         | St Bartholomew's Hospital                  |
| Dr Laura Assersohn               | St Georges Hospital                        |
| Dr Janine Mansi                  | St Georges Hospital                        |
| Carlo Palmeri                    | St Georges Hospital                        |
| Dr Tim Perren                    | St James's University Hospital             |
| Dr Frances Yuille                | St Johns Hospital                          |
| Name                        | Hospital                                      |
|-----------------------------|-----------------------------------------------|
| Mr Morgan                   | St Margaret's Hospital                        |
| Dr Ashraf Patel             | St Margaret's Hospital                        |
| Mr Raafat Gendy             | Staffordshire General Hospital                |
| Dr Chris Alcock             | Stoke Mandeville Hospital                     |
| Sanjoy Chatterjee           | Sunderland Royal Hospital                     |
| Dr Ujjal Mallick            | Sunderland Royal Hospital                     |
| Dr Leopold Reinecke         | Sunderland Royal Hospital                     |
| Mr. Alan Rich               | Sunderland Royal Hospital                     |
| Dr Kathryn Wright           | Sunderland Royal Hospital                     |
| Dr Ashraf Patel             | The Princess Alexandra Hospital NHS Trust     |
| Ian Manifold                | Thombury Hospital                             |
| Dr Kash Purohit             | Thombury Hospital                             |
| Dr Nigel Bailey             | Torbay Hospital                               |
| Dr Peter Donnelly           | Torbay Hospital                               |
| Dr Andrew Goodman           | Torbay Hospital                               |
| Dr Liz Whipp                | United Bristol Healthcare NHS Trust           |
| Dr Julie O'Hagan            | University Hospital Aintree                   |
| Dr Penny Schofield          | University Hospital Aintree                   |
| Dr A J Rathmell             | University Hospital of Hartlepool             |
| Dr Wendy Taylor             | University Hospital of North Durham           |
| Dr A Murray Brunt           | University Hospital of North Staffordshire    |
| Mr Colm Henessy             | University Hospital of North Tees             |
| Dr Peter Barrett-Lee        | Velindre Hospital                             |
| Prof. Robert J Grieve       | Walsgrave Hospital                            |
| Dr Nawaz Walji              | Warwick Hospital                              |
| Dr D A Jones                | Warwick Hospital                              |
| Prof. Robert J Grieve       | Warwick Hospital                              |
| Dr Anne Margaret Moody      | West Suffolk Hospital                         |
| Dr David Cameron            | Western General Hospital                      |
| Prof M Green                | Western General Hospital                      |
| Dr Angela Bowman            | Western General Hospital                      |
| Mr David George             | Western Infirmary, Glasgow                    |
| Name                          | Hospital                                  |
|-------------------------------|-------------------------------------------|
| Dr M J Tomlinson              | Weston General Hospital                    |
| Professor Rob Coleman         | Weston Park Hospital                       |
| Dr Richard Ashford            | Wexham Park Hospital                      |
| Dr Marcia Hall                | Wexham Park Hospital                      |
| Dr C Cottrill                 | Whipps Cross Hospital                     |
| Dr Alison Jones               | Whittington Hospital                      |
| Dr Johnathan Hicks            | Wishaw Hospital                            |
| Dr Helen Mackay               | Wishaw Hospital                            |
| Mrs Alison Lannigan (acting PI) | Wishaw Hospital                           |
| Dr Ashita Waterstone (acting PI) | Wishaw Hospital                           |
| Prof Nigel Bundred            | Withington Hospital (Wythenshawe)         |
| Dr Sankha Mitra               | Worthing Hospital                          |
| Dr David Dodwell              | York District Hospital                     |
| Dr Jill Bishop                | Ysbyty Gwynedd                            |
References

1. Global Burden of Disease Cancer Collaboration., Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology 2016 Dec 3. doi: 10.1001/jamaoncol.2016.5688. [Epub ahead of print]

2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nature Rev Cancer 2011; 11: 411-425.

3. Ursini-Siegel J, Siegel PM. The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Letters 2016; 380(1): 281-8.

4. Coleman RE., Marshall H., Cameron D., et al on behalf of the AZURE investigators. Breast cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011; 365: 1396-1405.

5. Coleman RE, Cameron D, Dodwell D, et al: Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomized open-label phase 3 trial. Lancet Oncology 2014; 15: 997–1006.

6. Early Breast Cancer Trialists Cooperative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet 2015; 386(10001): 1353-1361.

7. Hadji P, Coleman R, Wilson C et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology. 2016; 27(3): 379-90.

8. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 2017; 35(18): 2062-2081.

9. Hudis CA, Barlow WE, Constantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. Journal of Clinical Oncology 2007; 25: 2127-2132.

10. Coleman R, Hall A, Albanell J, et al. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the
international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. *Lancet Oncology* 2017; 18(11): 1543-1552.

11. Gregory WM, Bolland K, Whitehead J, Souhami RL. Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancer. British Journal of Cancer 1997; 76(4): 551-8.

12. Wilson C, Bell R, Hinsley S, et al. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. Eur J Cancer. 2018 Mar 12;94:70-78.

13. Coleman RE, Woodward E., Brown J., et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 127: 429-438, 2011.

14. Rathbone EJ., Brown JE., Marshall HC., et al. Osteonecrosis of the Jaw and Oral Health – Related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BiG1/04). Journal of Clinical Oncology 31/21:2685-2692, 2013

15. Okita Y, Kimura M, Xie R, et al. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB. *Science Signaling* 2017; 10(474): pii: eaak9397.

16. Shanjin Cao, Jianguo Liu, Lihua Song and Xiaojing Ma. The Protooncogene c-Maf Is an Essential Transcription Factor for IL-10 Gene Expression in Macrophages. *Journal of Immunology* 2005; 174(6): 3484-3492.

17. Lai CM, Lin KY, Kao SH, et al. Hedgehog signaling establishes precursors for germline stem cell niches by regulating cell adhesion. *Journal of Cellular Biology* 2017; 216(5): 1439-1453.

18. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. *Acta Oncologica* 2004; 43: 650-656.

19. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. *Clinical Cancer Research* 2007; 13(18 Pt 1): 5406-5410.

20. Gnant M, Mlineritsch B, Schippering W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. *New England Journal of Medicine* 2009; 360: 679-691.
21. Paterson AHG, Anderson SJ, Lembersky BC et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. *Lancet Oncology* 2012; 13: 734-742.

22. von Minckwitz G1, Möbus V, Schneeweiss A, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. *Journal of Clinical Oncology* 2013; 31(28): 3531-3539.

23. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. *Annals of Oncology* 2014; 25 Suppl 3: iii124-iii37.

24. Gralow J BW, Paterson AHG, Lew D et al: Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: *Journal of Clinical Oncology* 2015; 33, (suppl; abstr 503)

25. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2015; 386(9992): 433-443.

26. Coleman RE, Finklestein D, Barrios C et al. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study *Journal of Clinical Oncology* 2018; 36, (suppl; abstr 501)

27. Coleman R., Gnant M., Morgan G., Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. *Journal of National Cancer Institute* 2012; 104: 1059-1067.
Table 1: Baseline patient characteristics

| Allocation                              | Standard Treatment Alone | Standard treatment + ZOL |
|-----------------------------------------|--------------------------|--------------------------|
|                                         | Number | Percent | Number | Percent |
| **Lymph node involvement**              |        |         |        |         |
| 0 nodes involved                        | 32     | 1.9     | 30     | 1.8     |
| One - three nodes involved              | 1033   | 61.6    | 1042   | 62.0    |
| => four nodes involved                  | 607    | 36.2    | 604    | 35.9    |
| Unknown involvement                     | 6      | 0.4     | 5      | 0.3     |
| **Tumour stage**                        |        |         |        |         |
| T1                                      | 523    | 31.2    | 542    | 32.2    |
| T2                                      | 867    | 51.7    | 850    | 50.6    |
| T3                                      | 228    | 13.6    | 228    | 13.6    |
| T4                                      | 59     | 3.5     | 58     | 3.5     |
| TX                                      | 1      | 0.1     | 3      | 0.2     |
| **ER status**                           |        |         |        |         |
| ER positive                             | 1315   | 78.4    | 1318   | 78.4    |
| ER negative                             | 356    | 21.2    | 350    | 20.8    |
| ER unknown                              | 7      | 0.4     | 13     | 0.8     |
| **PR status**                           |        |         |        |         |
| Positive                                | 699    | 41.7    | 725    | 43.1    |
| Negative                                | 424    | 25.3    | 382    | 22.7    |
| Unknown/missing                         | 555    | 33.1    | 574    | 34.1    |
| **HER2 status**                         |        |         |        |         |
| Positive                                | 223    | 13.3    | 192    | 11.4    |
| Negative                                | 604    | 36.0    | 648    | 38.5    |
| Unknown/missing/not measured            | 851    | 50.7    | 841    | 50.0    |
| **Histological grade**                  |        |         |        |         |
| 1                                       | 141    | 8.4     | 146    | 8.7     |
| 2                                       | 708    | 42.2    | 731    | 43.5    |
| 3                                       | 787    | 46.9    | 765    | 45.5    |
| Not specified/missing                   | 42     | 2.5     | 39     | 2.3     |
| **Intended for neo-adjuvant therapy**   |        |         |        |         |
| Yes                                     | 107    | 6.4     | 105    | 6.2     |
| No                                      | 1571   | 93.6    | 1576   | 93.8    |
| **Intended systemic therapy plan**      |        |         |        |         |
| Endocrine therapy alone                 | 76     | 4.5     | 76     | 4.5     |
| Chemotherapy alone                      | 358    | 21.3    | 361    | 21.5    |
| Endocrine therapy and chemotherapy      | 1244   | 74.1    | 1244   | 74.0    |
| **Intended use of anthracyclines**      |        |         |        |         |
| Yes                                     | 1564   | 93.2    | 1568   | 93.3    |
| No                                      | 114    | 6.8     | 113    | 6.7     |
| **Intended use of taxanes**             |        |         |        |         |
| Yes                                     | 385    | 22.9    | 390    | 23.2    |
| No                                      | 1293   | 77.1    | 1291   | 76.8    |
| **Intended use of statins**             |        |         |        |         |
| Yes                                     | 100    | 6.0     | 97     | 5.8     |
| No                                      | 1578   | 94.0    | 1584   | 94.2    |
| **Menopausal status**                   |        |         |        |         |
| Pre-menopausal                          | 753    | 44.9    | 751    | 44.7    |
| Less than or equal to 5 years since     | 243    | 14.5    | 247    | 14.7    |
| menopause                               |        |         |        |         |
More than 5 years since menopause | 522 | 31.1 | 519 | 30.9
Menstrual status unknown | 160 | 9.5 | 164 | 9.8
**TOTAL** | 1678 | 100.0 | 1681 | 100.0

*Patients intended to receive endocrine therapy alone are included as ‘no’ to the ‘anthracyclines’ and ‘taxanes’ questions*

**Table 2: Recurrence events**

A – Disease Free Survival (DFS) as defined specifically for AZURE trial (see methods)

| 1st DFS event                                           | Standard Treatment [n=1678] number of events (%) | Standard Treatment + ZOL [n=1681] number of events (%) | Total [n=3359] number of events (%) |
|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------------|-------------------------------------|
| Loco-regional recurrence (excluding within conserved breast) | 106 (6.3%)                                       | 110 (6.5%)                                               | 216 (6.4%)                          |
| Distant Recurrence*                                     | 431 (25.7%)                                      | 403 (24.0%)                                               | 834 (24.8%)                          |
| • Bone                                                 | 244 (14.5%)                                      | 188 (11.2%)                                               | 432 (12.9%)                          |
| • Bone marrow                                          | 2                                                | 0                                                        | 2                                   |
| • Viscera                                              | 272                                              | 286                                                      | 558                                 |
| • CNS                                                  | 35                                               | 36                                                       | 71                                   |
| • Soft tissue and other                                 | 53                                               | 59                                                       | 112                                  |
| Death without recurrence                               | 63 (3.8%)                                        | 62 (3.7%)                                                 | 125 (3.7%)                          |
| Total DFS events                                       | 575 (34.3%)                                      | 555 (33.0%)                                               | 1130 (33.6%)                        |

The distant recurrence categories are not mutually exclusive hence the numbers (and percentages where presented) in each category do not equal the total number of patients with distant recurrences (as patients’ first DFS event). If a patient has more than one site of ‘viscera’ or ‘soft tissue and other’ distant recurrence reported on the same day as their 1st DFS event, all sites will be reported and the patient will appear more than once for each distant recurrence; percentages are therefore not presented for these categories.

B - Invasive Disease Free Survival (IDFS) as defined by STEEP guidelines

| 1st IDFS event                                           | Standard Treatment [n=1678] number of patients with event (%) | Standard Treatment + ZOL [n=1681] number of patients with event (%) | Total (n=3359) number of patients with event (%) |
|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-------------------------------------|
| Loco-regional recurrence                               | 127 (7.6%)                                       | 136 (8.1%)                                               | 263 (7.8%)                          |
| Distant Recurrence                                     | 405 (24.1%)                                      | 378 (22.5%)                                               | 783 (23.3%)                         |
| Contralateral breast cancer                             | 35 (2.1%)                                        | 22 (1.3%)                                                 | 57 (1.7%)                           |
### Table 3: Number of patients with each site of bone recurrence (as their first DFS recurrence).

| Site(s) of bone recurrence (as their first DFS recurrence)* | Standard treatment alone [n=1678] | Standard treatment + ZOL [n=1681] | Total [n=3359] |
|-----------------------------------------------------------|----------------------------------|----------------------------------|---------------|
|                                                           | number of patients with event (%)| number of patients with event (%)| number of patients with event (%) |
| Hip (femur)                                               | 44 (2.6%)                        | 25 (1.5%)                        | 69 (2.1%)     |
| Pelvis (not neck of femur)                                | 60 (3.6%)                        | 49 (2.9%)                        | 109 (3.2%)    |
| Spine (lumbar, thoracic, al, coccyx)                      | 153 (9.1%)                       | 119 (7.1%)                       | 272 (8.1%)    |
| Leg (below knee)                                          | 1 (0.1%)                         | 1 (0.1%)                         | 2 (0.1%)      |
| Arm                                                       | 21 (1.3%)                        | 7 (0.4%)                         | 28 (0.8%)     |
| Rib                                                       | 52 (3.1%)                        | 48 (2.9%)                        | 100 (3.0%)    |
| Scapula                                                   | 14 (0.8%)                        | 9 (0.5%)                         | 23 (0.7%)     |
| Sternum                                                   | 27 (1.6%)                        | 20 (1.2%)                        | 47 (1.4%)     |
| Clavicle                                                  | 3 (0.2%)                         | 4 (0.2%)                         | 7 (0.2%)      |
| Skull and facial bones                                    | 30 (1.8%)                        | 15 (0.9%)                        | 45 (1.3%)     |
| Mandible                                                  | 0 (0%)                           | 2 (0.1%)                         | 2 (0.1%)      |
| Others                                                    | 16 (1.0%)                        | 16 (1.0%)                        | 32 (1.0%)     |
| Bone marrow – no focal bone                               | 2 (0.1%)                         | 6 (0.4%)                         | 8 (0.2%)      |
| Unknown                                                   | 2 (0.1%)                         | 2 (0.1%)                         | 4 (0.1%)      |
| **Total**                                                 | **244 (14.5%)**                  | **188 (11.2%)**                  | **432 (12.9%)**|

* The categories of sites of bone recurrences are not mutually exclusive hence the numbers (and percentages) in each category do not equal the total number of patients with bone recurrences. If a patient has more than one site of bone recurrence reported on the same day as their first recurrence, all of the sites will be reported and the patient will appear more than once in the corresponding column.
Table 4: Characteristics of MAF tested sub-set and overall AZURE trial population

| Variable                          | FISH evaluable result (n=865) | Tumour Provided (n=1739) | AZURE population (n=3359) |
|-----------------------------------|-------------------------------|--------------------------|---------------------------|
| **Menopausal Status**             |                               |                          |                           |
| Non post-menopausal               | 590 (68.2%)                   | 1192 (68.5%)             | 2318 (69.0%)              |
| Post-menopausal                   | 275 (31.8%)                   | 547 (31.5%)              | 1041 (31.0%)              |
| **Age**                           |                               |                          |                           |
| <40                               | 87 (10.1%)                    | 198 (11.4%)              | 384 (11.4%)               |
| 40-49                             | 299 (34.6%)                   | 571 (32.8%)              | 1108 (33.0%)              |
| 50-59                             | 281 (32.5%)                   | 580 (33.4%)              | 1126 (33.5%)              |
| 60-69                             | 162 (18.7%)                   | 332 (19.1%)              | 628 (18.7%)               |
| 70+                               | 36 (4.2%)                     | 58 (3.3%)                | 113 (3.4%)                |
| **Lymph node involvement**        |                               |                          |                           |
| 0                                 | 2 (0.2%)                      | 17 (1.0%)                | 62 (1.8%)                 |
| 1-3                               | 563 (65.1%)                   | 1122 (64.5%)             | 2075 (61.8%)              |
| ≥4                                | 300 (34.7%)                   | 598 (34.4%)              | 1211 (36.1%)              |
| Unknown                           | 0 (0%)                        | 2 (0.1%)                 | 11 (0.3%)                 |
| **Tumour stage**                  |                               |                          |                           |
| T1                                | 274 (31.7%)                   | 577 (33.2%)              | 1065 (31.7%)              |
| T2                                | 475 (54.9%)                   | 901 (51.8%)              | 1717 (51.1%)              |
| T3                                | 99 (11.4%)                    | 214 (12.3%)              | 456 (13.6%)               |
| T4                                | 17 (2.0%)                     | 47 (2.7%)                | 117 (3.5%)                |
| TX                                | 0 (0.0%)                      | 0 (0.0%)                 | 4 (0.1%)                  |
| **ER status**                     |                               |                          |                           |
| ER positive                       | 689 (79.7%)                   | 1388 (79.8%)             | 2634 (78.4%)              |
| ER negative                       | 171 (19.8%)                   | 341 (19.6%)              | 705 (21.0%)               |
| ER unknown                        | 5 (0.6%)                      | 10 (0.6%)                | 20 (0.6%)                 |
| **Systemic therapy plan**         |                               |                          |                           |
| Endocrine therapy (ET)            | 46 (5.3%)                     | 89 (5.1%)                | 152 (4.5%)                |
| Chemotherapy (CT)                 | 166 (19.2%)                   | 339 (19.5%)              | 719 (21.4%)               |
| ET and CT                         | 653 (75.5%)                   | 1311 (75.4%)             | 2488 (74.1%)              |
| **Anthracyclines**                |                               |                          |                           |
| Yes                               | 794 (91.8%)                   | 1604 (92.2%)             | 3132 (93.2%)              |
| No                                | 71 (8.2%)                     | 135 (7.8%)               | 227 (6.8%)                |
| **Taxanes**                       |                               |                          |                           |
| Yes                               | 126 (14.6%)                   | 267 (15.4%)              | 775 (23.1%)               |
| No                                | 739 (85.4%)                   | 1472 (84.6%)             | 2584 (76.9%)              |
| **HER2 status**                   |                               |                          |                           |
| Positive                          | 93 (10.8%)                    | 186 (10.7%)              | 415 (12.4%)               |
| Negative                          | 250 (28.9%)                   | 503 (28.9%)              | 1251 (37.2%)              |
| Unknown / Not measured            | 522 (60.3%)                   | 1050 (60.4%)             | 1693 (50.4%)              |
| **Histological grade**            |                               |                          |                           |
| 1                                 | 61 (7.1%)                     | 147 (8.5%)               | 285 (8.5%)                |
| 2                                 | 333 (38.5%)                   | 748 (43.0%)              | 1439 (42.8%)              |
| 3                                 | 467 (54.0%)                   | 820 (47.2%)              | 1552 (46.2%)              |
| Not specified                     | 4 (0.5%)                      | 24 (1.4%)                | 83 (2.5%)                 |
| **PR status**                     |                               |                          |                           |
| Variable                  | FISH evaluable result (n=865) | Tumour Provided (n=1739) | AZURE population (n=3359) |
|--------------------------|-------------------------------|-------------------------|--------------------------|
| Positive                 | 308 (35.6%)                  | 633 (36.4%)             | 1423 (42.4%)             |
| Negative                 | 159 (18.4%)                  | 350 (20.1%)             | 806 (24.0%)              |
| Unknown                  | 398 (46.0%)                  | 756 (43.5%)             | 1130 (33.6%)             |

Table 5: Frequency of skeletal morbid events at 10 years according to treatment allocation

| Patients experiencing a SRE (\% of patients) | Standard Treatment Alone N=1678 | Standard Treatment + ZOL N=1681 | Total N=3359 |
|----------------------------------------------|---------------------------------|---------------------------------|--------------|
| Yes                           | 378 (22.5%)                     | 284 (16.9%)                     | 662 (19.7%)  |
| No                             | 1300 (77.5%)                    | 1397 (83.1%)                    | 2697 (80.3%) |

| Type of SRE (% of skeletal event by treatment arm) | Standard Treatment Alone N=1678 | Standard Treatment + ZOL N=1681 | Total N=3359 |
|---------------------------------------------------|---------------------------------|---------------------------------|--------------|
| Fracture                                          | 272 (58%)                       | 195 (42%)                       | 467          |
| Before DFS event                                  | 193 (58%)                       | 143 (42%)                       | 336          |
| After DFS event                                   | 79 (60%)                        | 52 (40%)                        | 131          |
| Radiation therapy to bone                        | 251 (67%)                       | 125 (33%)                       | 376          |
| Surgery to bone                                  | 106 (51%)                       | 103 (49%)                       | 209          |
| Spinal cord compression                           | 34 (65%)                        | 18 (35%)                        | 52           |
| Hypercalcemia                                     | 36 (57%)                        | 27 (43%)                        | 63           |
| Unclassified                                      | 1                               | 2                               | 3            |

| Total number of SRE (\% of SRE)                  | 700 (60%)                       | 470 (40%)                       | 1170         |

SRE, skeletal related event; DFS, disease free survival
Legend to Figures

Figure 1: CONSORT diagram
Figure 2: Disease free (DFS) and invasive disease free survival (IDFS) by treatment allocation (Top panels - ITT analysis; Bottom panels - women who were in established menopause (>5 years since last menses) at study entry).
Figure 3: Cumulative incidence of bone metastases as first DFS recurrence
Figure 4: Overall survival in the ITT analysis (A: left) and > 5 years postmenopausal subgroup (B: right).
Figure 5: Invasive disease free (IDFS) and overall survival (OS) by treatment allocation in the 79% of patients tested who did not over-express (copy number <2.5) the MAF gene.
Figure 6: Exploratory analyses investigating the impact of age at randomisation on disease outcomes with or without adjuvant zoledronic acid: A: top – All DFS events; B: middle – bone DFS events; C: bottom – all DFS other than bone events.
Figure 7: Exploratory analyses investigating the impact of age at randomisation on overall survival (top) and breast cancer survival (bottom) with or without adjuvant zoledronic acid.
Figure 8: Cumulative incidence function for time to confirmed osteonecrosis of the jaw for patients receiving zoledronic acid. No cases were reported in the control population.
